drugset / Trial / NCT00843934

Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

NCT00843934

Phase 2/3 Unknown 450 enrolled Nihon University
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare the efficacy and safety of cisplatin (CDDP) and epirubicin (EPI) in the treatment of transcatheter chemoembolization for Hepatocellular Carcinoma (HCC).

Timeline

Start
2009-03
Primary completion
2012-12
Completion
2015-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 65 mg/m2 Other
Subject Epirubicin Small molecule 60 mg/m2 Other